Background
==========

Keloid is a raised skin scar that is due to an aberrant response to skin injuries and is characterized by an excessive accumulation of extracellular matrix \[[@b1-medscimonit-20-2069]\]. The prevalence of keloid varies among different populations. The incidence can be as high as 16% in Africans. Compared to Caucasians, Asians also have a higher prevalence rate \[[@b2-medscimonit-20-2069],[@b3-medscimonit-20-2069]\]. Keloid is a complex condition with environmental and genetic risk-contributing factors. However, genetic factors play a very important role in the development and progression of keloid \[[@b4-medscimonit-20-2069]--[@b6-medscimonit-20-2069]\]. Several genetic polymorphisms have been identified to be associated with keloid risk \[[@b7-medscimonit-20-2069]--[@b9-medscimonit-20-2069]\].

Plasminogen activator inhibitor-1 (PAI-1), also known as endothelial plasminogen activator inhibitor, is the principal physiological inhibitor of the plasminogen activator/plasmin protease system \[[@b10-medscimonit-20-2069]\]. Increased PAI-1 activity has been noted to be a feature of fibrosis. Accumulating evidence shows there is a direct correlation between the extent of collagen accumulation in the process of injury repair and genetically determined level of PAI-1. In keloid tissue, PAI was dramatically increased. PAI-1 may contribute to keloid pathogenesis through increasing accumulation of collagen synthesized by keloid fibroblasts \[[@b11-medscimonit-20-2069],[@b12-medscimonit-20-2069]\].

Several polymorphisms within the PAI-1 gene influence PAI-1 levels and are associated with incidence of several diseases. Among these polymorphisms, the -675 4G/5G insertion-deletion mutation and the -844G/A single-nucleotide polymorphism (SNP) have received much attention \[[@b13-medscimonit-20-2069]--[@b16-medscimonit-20-2069]\]. So far, there is no study investigating the association between PAI-1 polymorphisms and the risk for KS. Based on this knowledge, we wondered whether these PAI-1 polymorphisms might be associated with keloid pathogenesis. The aim of the present study was to investigate the impact of -675 4G/5G and -844G/A polymorphisms in PAI-1 on susceptibility of keloid and serum PAI-1 level in a Chinese Han population.

Material and Methods
====================

Subjects
--------

We enrolled 241 patients with keloid from our hospital. The diagnosis of all cases was made by 2 independent physicians. The controls group consisted of 207 normal healthy individuals without a diagnosis of keloid, family history of keloid, or autoimmune disorders. The study was approved by our hospital's ethics committees and written informed consent was obtained from each subject.

Methods
-------

Blood specimens (10 ml) were collected from each individual. The genomic DNA was isolated with standard phenol-chloroform method. Plasma level of PAI-1 was measured by use of an AssayMax Human Plasminogen Activator Inhibitor-1 ELISA kit (AssayPro, St. Charles, MO, USA).

PAI-1 (-675) 4G/5G polymorphism and -844G/A polymorphisms were determined using a standard polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) assay.

PAI-1 (-675) 4G/5G
------------------

The primers used in PCR were: forward 5′-CAC AGA GAG AGT CTG GCC ACGT-3′ and reverse 5′-CCA ACA GAG GAC TCTTGG TCT-39CCACG-3′. Since (-675) 4G/5G polymorphism is a polymorphism based on the insertion-deletion of a G allele in PAI-1 promoter, the product of the PCR was 98 bp for the 4G allele and 99 bp for the 5G allele. FastDigest BslI (Fermentas ®, Thermo Scientific, Waltham, MA, USA) was used to digest the amplification product. Afterwards, digested fragments were analyzed by electrophoresis on 4% polyacrylamide gel. PAI-1 (-675) 5G allele showed 77-bp fragment, and PAI-1 (-675) 4G allele showed 98-bp fragment.

-844G/A
-------

The -844G/A polymorphism was determined by PCR-RFLP, using the following primers: forward, 5′-CAGGCTCCCACTGATTCTAC-3′; and reverse, 5′-GAGGGCTCTCTTGTGTCAAC-3′. Amplified fragments were digested with FastDigest XhoI (Fermentas^®^, Thermo Scientific, Waltham, MA, USA) and analyzed by 3% agarose gel electrophoresis. We obtained 314+146 bp fragments for -844G allele and 510-bp fragment for -844A allele.

Statistical analysis
--------------------

The *t* test was used to compare the clinical features between the keloid patients and controls. Chi-square tests were used to analyze the genotype frequency and demographic distributions between cases and controls and to evaluate the Hardy-Weinberg equilibrium. Logistic regression analysis was used to determine the odds ratios (ORs) and 95% confidential intervals (CIs) for genotypes and alleles in keloid patients and controls. All statistical analyses were performed with SPSS version 17.0 software (SPSS Company, Chicago, Illinois, USA,). P\<0.05 was considered statistically significant.

Results
=======

The clinical features in the keloid and control groups are presented in [Table 1](#t1-medscimonit-20-2069){ref-type="table"}. There were no significant differences between keloid and control group in mean age, sex, or BMI (P\>0.05). KS patients had significantly higher plasma PAI-1 level than controls (P\<0.001). The distribution of PAI-1--844 A/G and -675 4G/5G polymorphisms were found to be in Hardy-Weinberg equilibrium for Keloid patients and controls (all P\>0.05)

The genotype distribution of PAI-1 -844 A/G and -675 4G/5G polymorphisms was not significantly different between the KS and controls (P\>0.05) ([Table 2](#t2-medscimonit-20-2069){ref-type="table"}). However, the distribution of 4G/5G genotypes was significantly different between the keloid group and the controls. The frequencies of 4G/4G, 4G/5G, and 5G/5G genotypes were 39%, 47%, and 14%, respectively, in the KS patients. The prevalence of the -675 4G/4G genotype was markedly higher in keloid patients than in controls (39% *vs.* 28%, P=0.041). With 4G/5G of as reference, the statistic analysis showed the 4G/4G genotype carriers had a higher chance of having KS (OR=1.549, 95% CI 1.017--2.358). Similarly, the PAI-1 gene 4G allele was significantly higher in keloid patients compared with controls (62.2% *vs.* 54.1%, P=0.014). These differences represented an increased risk of keloid as evidenced by the OR of 1.395 (95% CI 1.069--1.822).

We analyzed the influence of the PAI-1 -844 A/G and -675 4G/5G polymorphisms on the serum PAI-1 levels ([Table 3](#t3-medscimonit-20-2069){ref-type="table"}). Keloid patients had significantly higher PAI-1 levels than the control group (23.00±3.98) *vs.* (20.25±2.45) ng/ml, P\<0.0001) ([Table 1](#t1-medscimonit-20-2069){ref-type="table"}). As shown in [Table 3](#t3-medscimonit-20-2069){ref-type="table"}, the plasma PAI-1 level was significantly higher in patients with 4G/4G genotype than those without 4G/4G genotypes. Keloid patients with 4G/4G genotype had remarkably higher PAI-1 levels than those subjects with 4G/4G genotype in the control group (P\<0.001). However, when comparing keloid patients and controls with other genotypes, we did not find any other genotypes that could affect the plasma PAI-1 level.

Discussion
==========

In the present study, we investigated the effect of 2 PAI-1 gene polymorphisms on risk of KS in a Chinese Han population. PAI-1 has been shown to be crucial to the plasminogen activator/plasmin protease system. It plays an important role in a wide variety of physiologic and pathologic processes, including fibrosis, fibrinolysis, wound healing, and cancer metastasis. In normal skin, PAI-1 was present at low levels, whereas in keloid tissue PAI was dramatically increased. Emerging evidence demonstrates that the relationship between PAI-1 and collagen accumulation is an important mechanism in the development of keloid \[[@b11-medscimonit-20-2069],[@b12-medscimonit-20-2069]\].

There are many reports indicating that several common polymorphism of the PAI-1 gene are risk factors for various diseases related to the elevated serum levels of PAI-1 \[[@b13-medscimonit-20-2069],[@b17-medscimonit-20-2069]\]. However, to the best of our knowledge, this is the first study to investigate the association between PAI-1 polymorphisms with the risk of keloid. We demonstrated that the PAI-1 -675 4G/5G polymorphism, but not -844 A/G polymorphism, was associated with keloid incidence. Our findings show that PAI-1 -675 4G/4G carriers had a higher risk of developing keloid. Several studies reported that the PAI-1 -844 A/G polymorphism may contribute to the risk of some diseases \[[@b18-medscimonit-20-2069],[@b19-medscimonit-20-2069]\]. However, in the present study, no evidence was found of a relationship between this variant and the risk of keloid.

In the present study, keloid subjects had a significantly higher mean plasma PAI-1 level than controls. Previous studies showed that the -675 4G/5G promotor polymorphism of PAI-1 may modulate PAI-1 transcription. The 4G allele insertion/deletion promoter polymorphism has been associated with elevated plasma levels of PAI-1 \[[@b13-medscimonit-20-2069],[@b17-medscimonit-20-2069]\]. Our study demonstrated that the patients with 4G/4G genotype had a significantly higher plasma PAI-1 level compared with 4G/5G genotype and 5G/5G genotype. Keloid patients with 4G/4G genotype had remarkably higher plasma PAI-1 level than those subjects in the control group. Collectively, our findings provide evidence that PAI-1 plays an important role in the development of KS. The -675 4G/5G gene polymorphisms of PAI-1 and the circulating PAI-1 are associated with risk of keloid.

Conclusions
===========

In conclusion, our study presents evidence of an association of PAI-1 -675 4G/5G polymorphism with keloid risk and plasma PAI-1 levels in a Chinese Han population. Since this was a single-center study and the number of subjects was relatively small, it is necessary to perform larger studies investigating the genetics of keloid.
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###### 

The clinical characteristics of all subjects.

                       Keloid group (n=242)   Control group (n=207)   P value
  -------------------- ---------------------- ----------------------- ---------
  Sex (F: M)           105: 137               98: 109                 0.401
  Age                  22.1±2.36              21.3±2.14               0.244
  BMI                  23.6±1.81              22.9±1.95               0.556
  Race or ethnicity    Chinese Han            Chinese Han             1
  Plasma PAI-1 level   23.02±3.98             20.25±2.45              \<0.001

###### 

The genotype and the allele frequencies of PAI-1 gene polymorphism in subjects and relative risk for keloid compared with controls.

                              Keloid group n (%)   Control group n (%)   OR             95% CI         P value
  -------------- ------------ -------------------- --------------------- -------------- -------------- ---------
  (-675) 4G/5G   4G/4G        94 (38.8)            58 (28.0)             1.549          1.017--2.358   0.041
  5G/4G          113 (46.7)   108 (52.2)           1 (reference value)                                 
  5G/5G          35 (14.5)    41 (19.8)            0.816                 0.484--1.376   0.445          
  5G             183 (37.8)   190 (45.9)           1 (reference value)                                 
  4G             301 (62.2)   224 (54.1)           1.395                 1.069--1.822   0.014          
  -844A/G        GG           63 (26.0)            68 (32.9)             0.746          0.484--1.150   0.184
  AG             123 (50.8)   99 (47.8)            1 (reference value)                                 
  AA             56 (23.1)    40 (19.3)            1.127                 0.694--1.829   0.629          
  G              249 (51.4)   186 (56.8)           1 (reference value)                                 
  A              235 (48.6)   1794 (3.2)           1.239                 0.952--1.613   0.111          

###### 

The plasma PAI-1 levels of keloid patients and controls in each genotype of PAI-1 polymorphism.

                             Keloid group (ng/ml)   Control group (ng/ml)   P value
  ------------- ------------ ---------------------- ----------------------- ---------
  (-675)4G/5G   4G/4G        26.34±3.52             22.14±3.36              \<0.001
  5G/4G         20.71±2.41   21.18±2.99             0.201                   
  5G/5G         21.86±3.07   23.34±3.78             0.067                   
  -844A/G       GG           21.25±2.91             20.44±2.43              0.086
  AG            23.98±4.09   22.99±3.51             0.059                   
  AA            23.09±4.12   21.55±3.39             0.056                   
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